Cervomed Inc. · NASDAQ:CRVO
Cervomed — Investor Presentation (September 2023)
20 slides from Cervomed's investor presentation, Sep 6, 2023
Slide 1: Corporate Overview: Medicines for the Brain
$ CERVOMED “Medicines for the Brain” Corporate Overview NASDAQ: CRVO ‘voh), noun, in French for brain or.
Slide 2: Forward-looking statements
itanisinaiien § CERVOMED This presentation includes express and implied forward Jooking statements within the meaning of the Private Securtes Litigation Reform Act of 1995, as amended, regarding the intentions, plans, beliefs, expectations or forecasts for the future of CervoMed Inc. (the “Company”
Slide 3: CervoMed at a Glance
CervoMed at a Glance § cCERVOMED CNS Company Differentiated approach to age-related neurologic disorders with a late-stage lead clinical asset; pipeline of additional indications and second asset Phase 2b Ready Lead Drug Candidate Neflamapimod has the potential to be the first disease-modifying trea
Slide 4: CervoMed Management Team
CervoMed Management Team $ CERVOMED ‘John Alam, MD President, CEO & Co-Founder, Director Robert J. Cobuzzi Jr, PRD — Chief Operating Omicer + Former Chief Maciol fic and EVP MadicineaDevelopmant 1 Proncent Chie Seca ter ancDiecor of ifan sine 2020 Vener {how thon 38 year of some tuncional esdasnipan
Slide 5: Non-Employee Directors and Advisors
Non-Employee Directors and Advisors § cCERVOMED DIRECTORS Sylvie Gregoire, PharmD (Chair) * Foomer Execute Chae and Co-Founder of Pharma + Board member, Novo Norsk, Reviy (ths Perkin Emer), F26 + Foomer President, Human Genets erapies, She + Foner Executve VP, Bogen, CEO, GyeaFi. ‘Former Board membe
Slide 6: CervoMed Pipeline
CervoMed Pipeline § CERVOMED EIP Commercial PRECLINICAL PHASE PHASE 2 PHASE Rights NEFLAMAPIMOD Dementia with Lewy bodies* Recovery after Anterior Circulation Ischemic Stroke ww ENTERING PHASE 28 ww PHASE 2 READY Early-onset Alzheimer’s Disease (EOAD) EIP200 (novel co-crystal) Multiple CNS ww *Recel
Slide 7: Opportunity for Therapeutics Targeting Basal Forebrain Cholinergic Degeneration
Opportunity for Therapeutics Targeting Basal Forebrain Cholinergic Degeneration + Age-related degeneration of the basal forebrain cholinergic system plays major role in many neurologic disorders: + Dementia with Lewy bodies (DLB), where itis the primary pathology + Early stages of Alzheimer’s: + Imp
Slide 8: Dementia with Lewy Bodies (DLB)
Dementia with Lewy Bodies (DLB) What is DLB? + Disease associated with abnormal deposits of a protein called alpha- ‘synuclein in the brain. These deposits, called Lewy bodies, affect chemicals, inthe brain whose changes, in tum, can lead to problems with thinking, movement, behavior, and mood1 + Pa
Slide 9: Neflamapimod for DLB: Positioned for Success
Neflamapimod for DLB: Positioned for Success ‘ature communicaions Fy Preclinical and randomized clinical evaluation of the p38a kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration aoe Ying ease oan Seen la — Peete peers or entre “The authors show in an animal model and in a st
Slide 10: Neflamapimod Reverses Cholinergic Dysfunction and Degeneration
Neflamapimod Reverses Cholinergic Dysfunction and Degeneration § CERVOMED Down Syndrome (0S) mice Cholinergic neurons in basal forebrain + Transgenic mice that have both DS-lke defects MeaiyMiceTcnted —MeatnyMicaieted—OSMcaToated OS Mice Treat during early development and adult-onset basal forebrain
Slide 11: Phase 2a Exploratory Clinical Study in Dementia with Lewy Bodies
Phase 2a Exploratory Clinical Study in § cCERVOMED Dementia with Lewy Bodies (DLB) GiscenD-LB = | Outcome Measures Patients + DLB-specic + Mig-to-Moderate DLB Neuropsychological Test tonserouseriena| * Battery (TB, 2 cognitive test battery) (Wekeith, Neurology, 2017) ee a, ; + Abnormal dopamine upta
Slide 12: AscenD-LB Outcome Measures
AscenD-LB Outcome Measures Ss GscenD-LB Clinical Dementia Rating Sum of Boxes Timed Up and Go Test Neuropsychological Test Battery (CDR-SB, Total Score = 0-18) (TUG, scored in seconds) (nTB)*: Cognitive Domains: * Detection + Memory (0-3) Eas awe + Identification * Orientation (0-3) * Judgement and
Slide 13: AscenD-LB Clinical Trial Results
AscenD-LB Clinical Trial Results § CERVOMED GscenD-LB + Neflamapimod significantly (p=0.023) improved dementia severity (assessed by CDR-SB) compared to placebo and also showed significant (p=0.044) improvement on motor function (assessed by TUG test) compared to placebo + Dose-response demonstrated
Slide 14: September 2023 Press Release
September 6 2023 Press Release $ ceRVOMED CervoMed Announces Publication in the Journal Neurology® Results Showing a Blood Test at Study Entry Identified Patients Who Demonstrated Substantial Response to Neflamapimod Treatment in Dementia with Lewy Bodies “The results support our long-standing thesi
Slide 15: Biomarker Results Support Enrichment Strategy for Phase 2b
Biomarker Results Support Enrichment § CERVOMED Strategy for Phase 2b + 35-50% of patients with DLB have biomarker Cohen's d Effect Size at 40mg TID vs. Placebo evidence of Alzheimer's disease (AD) co- pathology + Represent patients with extensive CDR-SB neurodegeneration (nerve cell loss) + DLB pat
Slide 16: Phase 2b Confirmatory Study in DLB
Phase 2b Confirmatory Study in DLB § cCERVOMED RewinD-LB Patients I] I | Outcome Measures 4°: COR-Sum of Boxes + DLB by consensus cee can + % Gopnton assessed by Hearobay. 217) Neuropeyehoogcal Test + Abnormal dopamine Battery (NTB), CGIC; Motor uptake by DaTscan™ Function, assessed by Timed + Globa
Slide 17: Neflamapimod for DLB: Well-Positioned
Neflamapimod for DLB: Well-Positioned § CERVOMED Commercially Growth in Di >$3B Peak Rate US Sales for First to Market
Slide 18: Key Upcoming Anticipated Milestones/Catalysts
Key Upcoming Anticipated Milestones/Catalysts 1H 2023 2H 2023 ma NIA approves $21M grant for v Phase 2b y Signed merger agreement with Diffusion Pharma Present data at ADIPD 2023 v Initiate Phase 2b DLB study a FPD in Phase 2b DLB study Close merger transaction; begin trading as a public company Pub
Slide 19: Summary
Summary $ cERVOMED ‘) Differentiated Approach to Age-related Neurologic Disorders with a Late-Stage Asset Major value creation potential in phase 2b read-out in dementia with Lewy bodies Experienced Management Team and Board of Directors Potential to broaden opportunity through additional indication
Slide 20: Corporate Overview: Medicines for the Brain
$ CERVOMED “Medicines for the Brain” Corporate Overview NASDAQ: CRVO ), oun, in French for brain or mind